2025
Pediatric Nonfatal Firearm Injury Health Care Utilization.
Du J, Andrews A, Gastineau K, Lee L, Ranney M, Sacks C, Song Z, Fleegler E, Pulcini C. Pediatric Nonfatal Firearm Injury Health Care Utilization. 2025, 156 PMID: 40555422, DOI: 10.1542/peds.2024-070424.Peer-Reviewed Original ResearchConceptsFirearm injuriesHealth care outcomesHealth care useHealth care utilizationMental health diagnosesPediatric firearm injuriesHealth care spendingCare outcomesCare useInjury preventionCare utilizationPostinjury careInjured childrenHealth diagnosisCare spendingPrevention effortsHealth impactsIntervention effortsHealthLongitudinal researchChildrenPostinjuryCost-effectiveFirearmUnited StatesCost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysis
Jin E, Ahmed A, Bekker L, Rousseau E, Dugdale C, Flanagan C, Wallace M, Freedberg K, Orrell C, Reddy K, Paltiel A, Ciaranello A, Neilan A. Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysis. The Lancet Global Health 2025, 13: e1230-e1239. PMID: 40441175, DOI: 10.1016/s2214-109x(25)00119-6.Peer-Reviewed Original ResearchConceptsHIV pre-exposure prophylaxisPre-exposure prophylaxisLife yearsIncremental cost-effectiveness ratioTDF-FTCCAB-LAAdolescent girlsYoung womenHIV-related careHealth-care sector perspectiveDaily oral tenofovir disoproxil fumarateIncrease life-yearsDaily oral TDF-FTCOral tenofovir disoproxil fumaratePrEP programmesCumulative HIV-transmissionHIV incidencePrEP persistenceTenofovir disoproxil fumarateCost-effectiveness ratioHIV transmissionCost-effectiveModel-projected outcomesSouth AfricaPrEP drugsBringing value to cancer research
Allen C, Danea H, Smieliauskas F, Edge S, Greenup R. Bringing value to cancer research. Frontiers In Oncology 2025, 15: 1580575. PMID: 40444101, PMCID: PMC12119247, DOI: 10.3389/fonc.2025.1580575.Peer-Reviewed Original ResearchPatient-reported outcomesPatient-centered cancer careIncreased administrative burdenQuality of lifeCancer careCancer clinical trialsEffective careFinancial toxicityMultidimensional visualization toolTime burdenCancer researchCollaborative approachAdministrative burdenCareCost-effectiveBurdenDecision-makingOutcomesCancerCurrent trialsClinical trialsTrialsCost analysisData interpretation complexCost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening
Ito S, Xicola R, Sra M, Potnis K, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz H, Llor X, Goshua G. Cost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening. Clinical Gastroenterology And Hepatology 2025 PMID: 40315972, DOI: 10.1016/j.cgh.2025.03.006.Peer-Reviewed Original ResearchLynch syndromeIncremental cost-effectiveness ratioGermline testingColorectal cancerProspective Lynch Syndrome DatabaseColorectal cancer probandsNational Cancer Institute's SurveillancePre-/post-interventionPreventing cancer incidenceLynch syndrome screeningEnd Results ProgramCost-effective interventionHealth system perspectiveCost-effectiveCancer incidenceQuality-adjusted life expectancyInstitute's SurveillanceResults ProgramProspective interventionStandard-of-careCost-effectiveness ratioLS testingCohort studyGenetic testingPrimary outcomeProphylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis.
Ito S, Potnis K, Harvey J, Sra M, Bewersdorf J, Bona R, Krumholz H, Cuker A, Pandya A, Goshua G. Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2025, 178: 819-828. PMID: 40258278, PMCID: PMC12170149, DOI: 10.7326/annals-24-02749.Peer-Reviewed Original ResearchConceptsEquity weightsSevere hemophilia AInequality aversion parameterFactor VIIIHemophilia AAversion parameterCost-effectiveness analysisEquity standardsCost-effectiveness of prophylaxisTime horizonOnce-weekly prophylaxisPriceAnnualized bleeding rateIncremental cost-effectiveness ratioFactor VIII prophylaxisScenario analysisCost-effectiveness ratioUnited StatesLifetime QALYsBleeding rateProphylaxisNational Institutes of HealthCost-effectiveInstitutes of HealthAlfaCost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi
Wenger C, Asare E, Kwon J, Li X, Mwinjiwa E, Chinkhumba J, Jere K, Hungerford D, Cunliffe N, Paltiel A, Pitzer V. Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi. PLOS Global Public Health 2025, 5: e0004341. PMID: 40209158, PMCID: PMC11984971, DOI: 10.1371/journal.pgph.0004341.Peer-Reviewed Original ResearchDose of RotarixNeonatal vaccinationThird doseDisability-adjusted life yearsRotavirus vaccination strategiesVaccination strategiesVaccination scheduleRV3-BB vaccineRotavirus vaccine scheduleModerate-to-severeCurrent rotavirus vaccinesProbabilistic sensitivity analysesRV3-BBPrevent rotavirusRotavirus casesRotavirus vaccineWTP thresholdAlternate infantsVaccine impactSevere diarrheaWeeks of ageRotarixVaccine effectivenessCost-effectiveness analysisCost-effectiveSelecting Cost-Effectiveness Methods for Health Benefits Package Design: A Systematic Approach
Nemzoff C, Sweeney S, Baltussen R, Vassall A. Selecting Cost-Effectiveness Methods for Health Benefits Package Design: A Systematic Approach. International Journal Of Health Policy And Management 2025, 14: 8562. PMCID: PMC12089834, DOI: 10.34172/ijhpm.8562.Peer-Reviewed Original ResearchHealth benefits packageCost-effectiveness analysisHealth technology assessmentHealth benefit package designBenefit package designFollow-up surveyCost-effectiveCost-effectiveness analysis methodsCost-effectiveness modelHealth economicsLiterature reviewGlobal evidenceBenefit packageHealthPublic healthTechnology assessmentAssessment methodsSurvey of authorsExpert opinionMethod selectionPrioritization criteriaExtensive investmentLocal designAssess CEAssessmentCosts and cost-effectiveness of integrated screening for non-communicable diseases in TB contacts
Hamada Y, Mukora R, Pelusa R, Ntshiqa T, Shedrawy J, Velen K, Abubakar I, Charalambous S, Walker S, Rangaka M. Costs and cost-effectiveness of integrated screening for non-communicable diseases in TB contacts. IJTLD OPEN 2025, 2: 160-165. PMID: 40092516, PMCID: PMC11906026, DOI: 10.5588/ijtldopen.24.0625.Peer-Reviewed Original ResearchNon-communicable diseasesDisability-adjusted life yearsNon-communicable disease screeningNon-communicable disease casesIncremental cost-effectiveness ratioIncremental costCardiovascular diseaseCross-sectional studyHigh riskCost-effectiveHousehold contact investigationCVD riskCare costsCost-effectiveness ratioHealthcare perspectiveAssessed patientsLife yearsProvider costsIntegrated screeningImprove cost-effectivenessPrioritising individualsContact investigationTB contactDrug costsRisk
2024
Recent advances in portable, low-field magnetic resonance imaging in cerebrovascular disease
Zabinska J, de Havenon A, Sheth K. Recent advances in portable, low-field magnetic resonance imaging in cerebrovascular disease. Current Opinion In Neurology 2024, 38: 35-39. PMID: 39624032, DOI: 10.1097/wco.0000000000001338.Peer-Reviewed Original ResearchConceptsCerebrovascular diseaseWhite matter hyperintensityHealthcare settingsHemorrhage managementAlzheimer's dementiaClinical timepointsStages of cerebrovascular diseaseHemorrhagic strokeEmergency settingWhite matter hyperintensitiesIntracerebral hemorrhage managementCardiovascular intensive careThrombolytic administrationPatient populationCerebrovascular disease progressionIntensive careMagnetic resonance imagingStrokeEndovascular reperfusionCerebrovascularCost-effectiveDisease progressionResonance imagingChronic stageCareEvaluating the Health and Economic Impacts of Return-to-Work Interventions: A Modeling Study
Morgante N, Bjørnelv G, Aasdahl L, Nguyen C, Fimland M, Kunst N, Burger E. Evaluating the Health and Economic Impacts of Return-to-Work Interventions: A Modeling Study. Value In Health 2024, 28: 415-423. PMID: 39579934, DOI: 10.1016/j.jval.2024.10.3850.Peer-Reviewed Original ResearchQuality-adjusted life yearsReturn to workO-ACTReturn-to-work interventionsHealth-related quality of lifeDecision-analytic modelRates of sickness absenceHealth-related qualityCost-effectiveQuality of lifeRTW interventionsProductivity lossSickness absenceSick leaveCost-effectiveness thresholdRegistry dataHealthcare costsNorwegian guidelinesHealthcare perspectiveLife yearsSocietal perspectiveEconomic evaluationInterventionTrial outcomesPsychological disordersCost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder
Lu T, Ryan D, Cadet T, Chawarski M, Coupet E, Edelman E, Hawk K, Huntley K, Jalali A, O'Connor P, Owens P, Martel S, Fiellin D, D'Onofrio G, Murphy S. Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. Annals Of Emergency Medicine 2024, 85: 205-213. PMID: 39570250, PMCID: PMC11845297, DOI: 10.1016/j.annemergmed.2024.10.001.Peer-Reviewed Original ResearchHealth care sector perspectiveImplementation facilitatorsOpioid use disorder careIncremental cost-effectiveness ratioCost-effectiveness ratioHealth care sector costsEducational strategiesImplementation facilitation strategyCost-effectiveness acceptability curvesLikelihood of cost-effectivenessCost-effectiveOpioid use disorderQuality-adjusted life yearsUse disorderPatient engagementAcademic EDED visitsAcceptability curvesStandard educationEmergency departmentLife yearsFacilitation strategiesMeasures of effectivenessHealthBuprenorphineCost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, PMCID: PMC12138910, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatmentCost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC)
Merz L, Ito S, Walkovich K, Achebe M, Van Havre N, Frustace P, Goshua G. Cost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC). Blood 2024, 144: 162. DOI: 10.1182/blood-2024-202605.Peer-Reviewed Original ResearchIncremental net monetary benefitAbsolute neutrophil countWork-upBirth cohortBase-caseCenters for Medicare & Medicaid ServicesMitigate patient harmCost-effective strategyUniversal testingUS health system perspectiveThreshold sensitivity analysisDiscounted quality-adjusted life yearsInfectious work-upHealth system perspectiveNo testBone marrow biopsyIncreased risk of infectionCross-sectional studyAnti-neutrophil antibodiesDiagnostic work-upQuality-adjusted life yearsUniversal testing strategiesUnited StatesCost-effectiveMarkov cohort modelAfrica Health Research Institute (AHRI) Household Contact study: a study protocol, statistical analysis and modelling plan
Khan P, Govender I, McCreesh N, Sweeney S, Sithole M, Ording-Jespersen G, Buthelezi X, Houben R, Baisley K, Smit T, Wong E, Hanekom W, White R, Vassall A, Fielding K, Grant A. Africa Health Research Institute (AHRI) Household Contact study: a study protocol, statistical analysis and modelling plan. Wellcome Open Research 2024, 9: 622. DOI: 10.12688/wellcomeopenres.22974.1.Peer-Reviewed Original ResearchAfrica Health Research InstituteQuantiFERON-TB Gold PlusHealth systemAntiretroviral treatmentReport symptomsCost-effectiveness of interventionsAntiretroviral treatment careRoutine health servicesDemographic surveillance areaTuberculosis case findingHealth Research InstituteM. tuberculosis transmissionChild household contactsPotential epidemiological impactTuberculosis screening strategiesHealthcare utilisationHIV testingHealth facilitiesPulmonary tuberculosisHealth servicesSymptom screeningCase findingCost-effectiveTuberculosis screeningEffects of antiretroviral treatmentIn-Office Needle Arthroscopy Is a Cost-Effective Alternative for Operating Room Diversion for Anterior Ankle Arthroscopy a Financial Analysis
Butler J, Gianakos A, Savage-Elliott I, Kennedy J. In-Office Needle Arthroscopy Is a Cost-Effective Alternative for Operating Room Diversion for Anterior Ankle Arthroscopy a Financial Analysis. Foot & Ankle Orthopaedics 2024, 9: 2473011424s00333. PMCID: PMC11682603, DOI: 10.1177/2473011424s00333.Peer-Reviewed Original ResearchIn-office needle arthroscopyAnterior ankle arthroscopyIn-officeAnkle arthroscopyRevision rateInfluence of patient preferencesPatient-reported outcome metricsStudent's t-testOperating suiteTwo-sample Student's t-testNeedle arthroscopyClinical trialsAnkle pathologyPatients' perceptionsPatient preferencesPatientsArthroscopyOutcome metricsT-testNext stepsSensitivity analysisCost-effectiveCost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealthCost‐effectiveness of a primary care‐based Healthy Weight Clinic compared with usual care
Sharifi M, Fiechtner L, Barrett J, O'Connor G, Perkins M, Reiner J, Luo M, Taveras E, Gortmaker S. Cost‐effectiveness of a primary care‐based Healthy Weight Clinic compared with usual care. Obesity 2024, 32: 1734-1744. PMID: 39192764, PMCID: PMC11361715, DOI: 10.1002/oby.24111.Peer-Reviewed Original ResearchConceptsHealthy weight clinicHealth care sectorObesity prevalenceIntervention costsCare sectorReducing obesity disparitiesNational implementationHealth care costsObesity disparitiesUsual careBMI changeCare costsFQHCsCost-effectiveSocietal perspectiveWhite populationHealthHealthyObesityQALYEstimated costInterventionClinicChildrenGreater reductionsNano-Arthroscopic Plantar Fascia Release Technique
Cho E, Butler J, Kennedy J, Gianakos A. Nano-Arthroscopic Plantar Fascia Release Technique. Arthroscopy Techniques 2024, 13: 103118. PMID: 39711889, PMCID: PMC11662860, DOI: 10.1016/j.eats.2024.103118.Peer-Reviewed Original ResearchPlantar fasciotomyCases of plantar fasciitisEndoscopic plantar fasciotomyReturn to activityRisk of soft tissuePlantar fasciitisPlantar fasciaHigh patient satisfactionPostoperative painEndoscopic techniquesPatient satisfactionDecreased riskOffice settingDecreased postoperative painNeurovascular injuryFasciotomyRecalcitrant casesOpen techniquePainCost-effectiveQuicker recoverySoft tissuePlantarSatisfactionUnit costs and cost-effectiveness of a device to improve TB treatment adherence in China
Sweeney S, Fielding K, Liu X, Thompson J, Dong H, Jiang S, Zhao Y, Huan S, Vassall A. Unit costs and cost-effectiveness of a device to improve TB treatment adherence in China. IJTLD OPEN 2024, 1: 299-305. PMID: 39035432, PMCID: PMC11257087, DOI: 10.5588/ijtldopen.23.0451.Peer-Reviewed Original ResearchIntervention cost-effectivenessHealth facility levelIncremental cost-effectiveness ratioProbabilistic sensitivity analysesTB treatment adherenceCluster-randomised superiority trialImprove treatment outcomesIncremental cost-effectivenessCost-effectiveness ratioIncremental costCost-effectiveDiscount rateUnit cost dataTreatment adherenceFacility levelLack of evidenceTreatment outcomesImprove adherenceDigital adherence technologiesEnhance patient managementScenario analysisSocietal perspectiveSuperiority trialStandard of careAdherence technologiesCost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States
Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States. Blood 2024, 143: 2332-2335. PMID: 38635764, PMCID: PMC11862817, DOI: 10.1182/blood.2024024209.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply